828 related articles for article (PubMed ID: 28874817)
21. [Not Available].
Alcazer V; Delenda C; Poirot L; Depil S
Bull Cancer; 2018 Dec; 105 Suppl 2():S178-S187. PubMed ID: 30686356
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of the antitumor effect of HER2-directed CAR-T cells through blocking epithelial-mesenchymal transition in tumor cells.
Zhang PF; Huang Y; Liang X; Li D; Jiang L; Yang X; Zhu M; Gou HF; Gong YL; Wei YQ; Li Q; Wang W
FASEB J; 2020 Aug; 34(8):11185-11199. PubMed ID: 32645243
[TBL] [Abstract][Full Text] [Related]
23. Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
[TBL] [Abstract][Full Text] [Related]
24. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy.
Rodriguez-Garcia A; Lynn RC; Poussin M; Eiva MA; Shaw LC; O'Connor RS; Minutolo NG; Casado-Medrano V; Lopez G; Matsuyama T; Powell DJ
Nat Commun; 2021 Feb; 12(1):877. PubMed ID: 33563975
[TBL] [Abstract][Full Text] [Related]
25. An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment.
Wang Y; Jiang H; Luo H; Sun Y; Shi B; Sun R; Li Z
Front Immunol; 2019; 10():1691. PubMed ID: 31379876
[TBL] [Abstract][Full Text] [Related]
26. Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response.
Li X; Daniyan AF; Lopez AV; Purdon TJ; Brentjens RJ
Leukemia; 2021 Feb; 35(2):506-521. PubMed ID: 32447345
[TBL] [Abstract][Full Text] [Related]
27. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
Gowrishankar K; Birtwistle L; Micklethwaite K
Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
[TBL] [Abstract][Full Text] [Related]
28. Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting.
Lee EHJ; Murad JP; Christian L; Gibson J; Yamaguchi Y; Cullen C; Gumber D; Park AK; Young C; Monroy I; Yang J; Stern LA; Adkins LN; Dhapola G; Gittins B; Chang WC; Martinez C; Woo Y; Cristea M; Rodriguez-Rodriguez L; Ishihara J; Lee JK; Forman SJ; Wang LD; Priceman SJ
Nat Commun; 2023 Aug; 14(1):4737. PubMed ID: 37550294
[TBL] [Abstract][Full Text] [Related]
29. Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment.
Yang Z; Pietrobon V; Bobbin M; Stefanson O; Yang J; Goswami A; Alphson B; Choi H; Magallanes K; Cai Q; Barrett D; Wang B; Qi LS; Marincola FM
J Transl Med; 2023 Feb; 21(1):158. PubMed ID: 36855120
[TBL] [Abstract][Full Text] [Related]
30. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
Siegler EL; Wang P
Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
[TBL] [Abstract][Full Text] [Related]
31. Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity.
McKenna MK; Englisch A; Brenner B; Smith T; Hoyos V; Suzuki M; Brenner MK
Mol Ther; 2021 May; 29(5):1808-1820. PubMed ID: 33571680
[TBL] [Abstract][Full Text] [Related]
32. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
[TBL] [Abstract][Full Text] [Related]
33. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity.
Fu W; Lei C; Liu S; Cui Y; Wang C; Qian K; Li T; Shen Y; Fan X; Lin F; Ding M; Pan M; Ye X; Yang Y; Hu S
Nat Commun; 2019 Sep; 10(1):4355. PubMed ID: 31554797
[TBL] [Abstract][Full Text] [Related]
34. Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade.
Srivastava S; Furlan SN; Jaeger-Ruckstuhl CA; Sarvothama M; Berger C; Smythe KS; Garrison SM; Specht JM; Lee SM; Amezquita RA; Voillet V; Muhunthan V; Yechan-Gunja S; Pillai SPS; Rader C; Houghton AM; Pierce RH; Gottardo R; Maloney DG; Riddell SR
Cancer Cell; 2021 Feb; 39(2):193-208.e10. PubMed ID: 33357452
[TBL] [Abstract][Full Text] [Related]
35. Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice.
Xie YJ; Dougan M; Jailkhani N; Ingram J; Fang T; Kummer L; Momin N; Pishesha N; Rickelt S; Hynes RO; Ploegh H
Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7624-7631. PubMed ID: 30936321
[TBL] [Abstract][Full Text] [Related]
36. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
37. Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer.
Rosewell Shaw A; Porter CE; Watanabe N; Tanoue K; Sikora A; Gottschalk S; Brenner MK; Suzuki M
Mol Ther; 2017 Nov; 25(11):2440-2451. PubMed ID: 28974431
[TBL] [Abstract][Full Text] [Related]
38. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12.
Chi X; Yang P; Zhang E; Gu J; Xu H; Li M; Gao X; Li X; Zhang Y; Xu H; Hu J
Cancer Med; 2019 Aug; 8(10):4753-4765. PubMed ID: 31237116
[TBL] [Abstract][Full Text] [Related]
39. CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.
Kuhn NF; Purdon TJ; van Leeuwen DG; Lopez AV; Curran KJ; Daniyan AF; Brentjens RJ
Cancer Cell; 2019 Mar; 35(3):473-488.e6. PubMed ID: 30889381
[TBL] [Abstract][Full Text] [Related]
40. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
